100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Samenvatting Farmacotherapie en Farmaceutische zorg 1 $11.95   Add to cart
Quickly navigate to
Preview
  2.  
  3. Universiteit Gent (UGent)
  4.  
  5. Farmaceutische Wetenschappen
  6.  
  7. Farmacotherapie en farmaceutische zorg 1 (J000425A)

Summary

Samenvatting Farmacotherapie en Farmaceutische zorg 1

2 reviews
 167 views  7 purchases
  • Course
  • Farmacotherapie en farmaceutische zorg 1 (J000425A)
  • Institution
  • Universiteit Gent (UGent)

Dit is een samenvatting voor het vak "farmacotherapie en farmaceutische zorg 1", gedoceerd in de eerste master. Het bevat een leidraad voor alle EUB's van de relevante geneesmiddelen. de samenvatting is opgebouwd uit de inhoud van de slides en lesnotities. Er wordt in de samenvatting duidelijk ge...

[Show more]

Preview 4 out of 156  pages

Document information

  • January 2, 2024
  • 156
  • 2023/2024
  • Summary

Subjects

  • farmacotherapie
  • farmaceutische zorg
  • eerste master
  • 1e master
  • master farmaceutische zor
  • farmacotherapie en farmaceutische zorg
  • farmaceutische wetenschappen
  • samenvatting
  • master geneesmiddelenontwikkeling

Written for

  • Universiteit Gent (UGent)
  • Farmaceutische Wetenschappen
  • Farmacotherapie en farmaceutische zorg 1 (J000425A)
All documents for this subject (1)

2  reviews

review-writer-avatar

By: okankaracam • 4 weeks ago

review-writer-avatar

By: lisedemeyst • 3 months ago

Seller

avatar-seller
lkfjqosidfj

Reviews received

Content preview

Farmaceutische zorg en farmacotherapie 1 2023 – 2024




Inhoudsopgave

Hoofdstuk 1.................................................................................................................................................... 4
1. Algemene inleiding .................................................................................................................................... 4
Wat is farmacotherapie? ................................................................................................................................ 4
Wat is farmaceu3sche zorg? ........................................................................................................................ 10
Zelfzorgadvies............................................................................................................................................... 12
Vermijden van medica3efouten – medica3ebewaking ................................................................................ 13
2. Therapietrouw ......................................................................................................................................... 13
Types niet-therapietrouw ............................................................................................................................. 14
3. Interac:es en geneesmiddelen ................................................................................................................ 15
Interac3emechanismen ............................................................................................................................... 15
Gevolgen van interac3es .............................................................................................................................. 16
Interac3es aLandelen ................................................................................................................................. 16
Arts contacteren ........................................................................................................................................... 17
4. Farmacokine:sche interac:es ................................................................................................................. 18
Interac3es ter hoogte van de absorp3e ....................................................................................................... 18
Interac3es ter hoogte van de distribu3e ...................................................................................................... 18
Interac3es ter hoogte van de metabolisa3e ................................................................................................ 18
Interac3es ter hoogte van de excre3e.......................................................................................................... 20
Interac3es ter hoogte van de PgP’s .............................................................................................................. 20
5. Farmacodynamische interac:es .............................................................................................................. 20
Hyperkaliëmie .............................................................................................................................................. 20
Bloedingsrisico ............................................................................................................................................. 21
Serotonine syndroom ................................................................................................................................... 22
QT interval .................................................................................................................................................... 22
Farmacologische antagonismen ................................................................................................................... 23
6. Farmacotherapie bij speciale popula:es ................................................................................................. 24
Zwangere vrouwen ....................................................................................................................................... 24
Vrouwen met kinderwens ............................................................................................................................ 25
Vrouwen die borstvoeding geven................................................................................................................. 25
Kinderen ....................................................................................................................................................... 26
Ouderen ....................................................................................................................................................... 26

Cardiovasculair stelsel .................................................................................................................................. 28
1. Cardiovasculair risicobeheer .................................................................................................................... 28
Apparently healthy people – risicobeheer ................................................................................................... 28
Pa3ënten met vastgesteld ASCVD ................................................................................................................ 29
Specifieke risico-condi3es ............................................................................................................................ 29
Risicobeheer: aanpak risicofactoren ............................................................................................................ 29
2. Diure:ca................................................................................................................................................... 33
3. ß-blokkers ................................................................................................................................................ 36
4. Calciumantagonisten ............................................................................................................................... 40
5. ACE-inhibitoren en sartanen .................................................................................................................... 41
ACE-inhibitoren ............................................................................................................................................ 41
Sartanen ....................................................................................................................................................... 45
6. ARNI: sacubitril/valsartan complex .......................................................................................................... 45
7. An:-ar:mica ............................................................................................................................................ 46

,Farmaceutische zorg en farmacotherapie 1 2023 – 2024


8. Nitraten.................................................................................................................................................... 49
9. Hypolipemiërende middelen .................................................................................................................... 51
Sta3nes......................................................................................................................................................... 51
PCSK9-inhibitoren ........................................................................................................................................ 55
10. An:trombo:ca .................................................................................................................................... 56
An3-aggregan3a ........................................................................................................................................... 57
An3coagulan3a ............................................................................................................................................ 58
Aandachtspunten an3trombo3ca ................................................................................................................ 62
11. Digoxine ............................................................................................................................................... 63

Gastro-intes:naal stelsel .............................................................................................................................. 64
1. Medica:ebegeleiding bij PPI’s ................................................................................................................. 64
Farmacologie van de PPI’s ............................................................................................................................ 64
Uitgicebegeleiding ....................................................................................................................................... 64
Problema3ek rond onnodig PPI gebruik ...................................................................................................... 65
2. Medica:ebewaking bij PPI’s .................................................................................................................... 66
CYP2C19 ....................................................................................................................................................... 66
GM waarvan BB aLankelijk is van de gastro-intes3nale pH ........................................................................ 66
3. Medica:ebegeleiding bij aminosalicylaten.............................................................................................. 66
4. Maagklachten bij NSAID-gebruikers ........................................................................................................ 67
5. Zelfzorg .................................................................................................................................................... 68
Refluxklachten & brandend maagzuur ......................................................................................................... 68
Dyspepsie ..................................................................................................................................................... 70
Nausea & braken .......................................................................................................................................... 70
Diarree ......................................................................................................................................................... 72
Cons3pa3e ................................................................................................................................................... 74
Proctologische aandoeningen, Aambeien en anale fissuren........................................................................ 78
Diarree/GI klachten bij colchicine toxiciteit ................................................................................................. 79
Preven3e opiaat – obs3pa3e ....................................................................................................................... 79

Astma en COPD ............................................................................................................................................ 80
1. Astma vs COPD......................................................................................................................................... 80
2. Therapeu:sche klassen van inhala:emedica:e ...................................................................................... 81
ß2 agonisten (BA) ......................................................................................................................................... 81
Inhala3ecor3costeroïden ............................................................................................................................. 81
ICS + ß2 combina3e ...................................................................................................................................... 81
An3cholinergica: muscarine antagonisten (MA) .......................................................................................... 81
SABA + SAMA combina3e ............................................................................................................................ 82
LABA + LAMA combina3e ............................................................................................................................. 82
ICS + LABA + LAMA: single inhaler triple therapy ......................................................................................... 82
3. Behandelingsplan ASTMA ........................................................................................................................ 82
Monoklonale an3lichamen in astma behandeling ....................................................................................... 82
4. Behandelingsplan COPD .......................................................................................................................... 83
Behandeling GOLD groep B .......................................................................................................................... 83
Behandeling GOLD groep D .......................................................................................................................... 83
Behandeling acute exacerba3e COPD .......................................................................................................... 83
5. Medica:ebegeleiding .............................................................................................................................. 84
Astma ........................................................................................................................................................... 84
COPD ............................................................................................................................................................ 84
6. Medica:ebewaking ................................................................................................................................. 88

,Farmaceutische zorg en farmacotherapie 1 2023 – 2024


Geneesmiddelinterac3es ............................................................................................................................. 88
Contra-indica3es .......................................................................................................................................... 89
Zwangerschap en borstvoeding ................................................................................................................... 90
Andere aandachtspunten ............................................................................................................................. 90
7. Zelfzorg bij astma en COPD pa:ënten ..................................................................................................... 91
Astma ........................................................................................................................................................... 91
COPD ............................................................................................................................................................ 91

Diabetes ....................................................................................................................................................... 92
Insuline – begeleiding .................................................................................................................................. 92
Orale an3diabe3ca – begeleiding................................................................................................................. 94
Pre-opera3ef beleid bij an3diabe3ca ........................................................................................................... 97
Extra informa3e............................................................................................................................................ 97
Medica3ebewaking ...................................................................................................................................... 98
Zelfzorg bij diabe3ci ..................................................................................................................................... 99

Schildklierpathologie ...................................................................................................................................101
Medica3ebegeleiding ................................................................................................................................. 102
Medica3ebewaking .................................................................................................................................... 103

Systemische cor:costeroïden ......................................................................................................................105
Medica3ebegeleiding ................................................................................................................................. 105
Medica3ebewaking .................................................................................................................................... 107

An:concep:e ..............................................................................................................................................108
1. Homonale an:concep:e – indeling ....................................................................................................... 108
Oestroprogestagene associa3es................................................................................................................. 108
Progestagenen ........................................................................................................................................... 109
IUD ............................................................................................................................................................. 109
Andere........................................................................................................................................................ 109
2. Menopauzale klachten ........................................................................................................................... 109
3. Farmaceu:sche zorg bij an:concep:e en menopauzale klachten ......................................................... 110
Medica3ebegeleiding ................................................................................................................................. 110
Medica3ebewaking .................................................................................................................................... 113
Noodan3concep3e ..................................................................................................................................... 115
4. Zelfzorg bij menstrua:epijn ................................................................................................................... 116
Niet medicamenteus advies ....................................................................................................................... 117
Medicamenteus advies .............................................................................................................................. 117

Urogenitale problemen en urineweginfec:es ..............................................................................................118
1. Urogenitale problemen .......................................................................................................................... 118
Blaasfunc3estoornissen ............................................................................................................................. 118
Benigne prostaathypertrofie/mic3eklachten bij mannen .......................................................................... 119
Vaginale klachten ....................................................................................................................................... 120
Impoten3e.................................................................................................................................................. 121
Bedplassen ................................................................................................................................................. 122
2. Farmacotherapie bij urineweginfec:es (UWI) ....................................................................................... 122
Acute cys33s/blaasontsteking.................................................................................................................... 122
Recidiverende cys33s ................................................................................................................................. 123
Acute pyelonefri3s ..................................................................................................................................... 123
Asymptoma3sche bacteriurie .................................................................................................................... 124

, Farmaceutische zorg en farmacotherapie 1 2023 – 2024


Pijn en koorts ..............................................................................................................................................125
1. Achtergrond ........................................................................................................................................... 125
Types pijn ................................................................................................................................................... 125
Biopsychosociaal model ............................................................................................................................. 125
Behandeldoel ............................................................................................................................................. 125
2. Behandeling van pijn ............................................................................................................................. 126
Niet medicamenteus .................................................................................................................................. 126
Medicamenteus ......................................................................................................................................... 127
Cannabis/cannabinoïden ........................................................................................................................... 129
Opioïdencrisis in USA ................................................................................................................................. 129
Opioïdrota3e .............................................................................................................................................. 130
3. Farmaceu:sche zorg bij pijn .................................................................................................................. 130
Paracetamol ............................................................................................................................................... 130
Opioïden..................................................................................................................................................... 131
4. Farmaceu:sche zorg bij koorts .............................................................................................................. 135
Achtergrond ............................................................................................................................................... 135
Niet-medicamenteus advies ....................................................................................................................... 136
Medicamenteus advies .............................................................................................................................. 136

Osteo-ar:culaire aandoeningen ..................................................................................................................138
1. Systemische NSAID’s .............................................................................................................................. 139
Medica3ebegeleiding ................................................................................................................................. 139
Medica3ebewaking .................................................................................................................................... 145
2. Farmaceu:sche zorg bij osteoar:culaire aandoeningen ....................................................................... 146
Reumatoïde artri3s .................................................................................................................................... 146
Jicht ............................................................................................................................................................ 149
Artrose: slijtagereuma ................................................................................................................................ 151
3. Farmaceu:sche zorg bij osteoporose ..................................................................................................... 152
Achtergond ................................................................................................................................................. 152
Behandeling osteoporose .......................................................................................................................... 152
Farmaceu3sche zorg bij osteoporose ......................................................................................................... 154



Hoofdstuk 1
1. Algemene inleiding
Wa t i s f a r m a c o t h e r a p i e?
Doel: optimale behandeling van patiënten met geneesmiddelen.

GM = essentiële tool om klachten of aandoeningen te behandelen of te voorkomen.
à geneesmiddelengebruik, moet altijd rationeel gebeuren.

Maar:
- GM kunnen (ernstige) problemen veroozaken
- Door slecht gebruik à ineffectiviteit
- Kostelijk
- Als apotheker is het belangrijk te realiseren welke patiënten baat hebben aan een geneesmiddelen en welke
hier juist een risico oplopen.

Wees steeds in staat om medicatie als een deel van behandelingsstrategiën te zien, vaak of soms is de niet-
medicamenteuze behandeling belangrijker.

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller lkfjqosidfj. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $11.95. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

81298 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$11.95  7x  sold
  • (2)
  Add to cart